Compare Amylx Pharmaceuticals Inc (AMLX) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Phillips 66 — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Phillips 66 trades at $191.3 (market cap $75.52B). The key difference: Phillips 66 is far larger — about 38.1× Amylx Pharmaceuticals Inc's market cap, and Phillips 66 pays a 2.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PSX | |
|---|---|---|
Market Cap | $1.98B | $75.52B |
Sector | Health | Energy |
52-Week High | $18.70 | $189.82 |
52-Week Low | $7.64 | $118.37 |
Enterprise Value | $1.70B | $97.49B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Phillips 66 (PSX) trades at $188.36, down 0.77% on the day, with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 18.6 and P/S of 0.57, while recent quarterly earnings have consistently beaten expectations. The company maintains a 14.75% ROE and recently declared a $1.27 quarterly dividend, reflecting management's confidence in cash flow stability.
PSX presents a compelling value opportunity with upside to the $196.57 consensus price target, supported by 57% analyst buy ratings. Key risks include refining margin volatility from Middle East disruptions and declining revenue trends from $170B in 2022 to $132.4B in 2025. The stock's technical overbought condition near resistance at $191 warrants caution despite positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
